Azenta, Inc.
PublicAzenta, Inc. is now publicly traded
The data on this page reflects Azenta, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Buyout/LBO
Feb 1, 2022
Est. Valuation at Exit
$3B
Total Funding Raised
$3B
Company Overview
Azenta, Inc. has raised $3B. It was founded in 1978.
Azenta, Inc. is a biotechnology company that provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies.
AI Layer
Non-AI
Azenta, Inc. Comparables
Compare Azenta, Inc. with similar companies based on industry and business-model similarity.
No comparables are published for Azenta, Inc.. Book a demo to ask about coverage.
Book a demoFor institutional investors. Book with your work email.
Azenta, Inc. Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Azenta, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Thomas H. Lee Partners | Buyout/LBO |
Recent news
Latest coverage and updates
- has_revenue_increased_byNov 11, 2026
Azenta, Inc. expects 3%-5% organic revenue growth for fiscal 2027, including mid-single-digit growth in Sample Management Solutions and low-single-digit growth in Multiomics.
- has_revenue_increased_byNov 10, 2026
Azenta, Inc. reports fiscal 2026 revenue of $622 million, up 5% year over year.
- licenses_technologyOct 30, 2026
On Oct 30th '26, Azenta, Inc. licenses technology from Elegen Corporation under an exclusive agreement as part of strategic investments in its GENEWIZ business.
- has_revenue_decreased_byOct 30, 2026
Azenta US, Inc. expects full-year fiscal 2026 Multiomics organic revenue to range from approximately down 1% to flat.
- has_revenue_increased_byOct 30, 2026
Azenta US, Inc. reports Multiomics revenue of $73 million, up 10% year over year for the period ended Jun 30th '26, with organic revenue up 8%, primarily driven by higher Next Generation Sequencing and Gene Synthesis revenue and partially offset by lower Sanger Sequencing revenue.
For institutional investors. Book with your work email.
Azenta, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.